By Josée Rose
Teva Pharmaceutical Industries swung to a fourth-quarter loss on lower revenue and an operating loss.
Shares fell about 2.5% in premarket trading to $20.99.
The company swung to a fourth-quarter loss of $217 million, or 19 cents a share, compared with net income of $461 million, or 41 cents a share, a year earlier. Adjusted earnings were 71 cents a share compared with $1 a year earlier.
Revenue fell to $4.23 billion from $4.46 billion a year earlier. The company noted the exchange rate hurt overall revenue by $8 million in the quarter.
Analysts polled by Factset expected an adjusted profit of 71 cents a share and revenue of $4.15 billion.
Teva said its fourth-quarter operating loss was $29 million, compared to an operating income of $755 million a year earlier.
Teva said its generics business continued growing across the globe.
For 2025, the company expects adjusted earnings of $2.35 to $2.65 a share and revenue between $16.8 billion and $17.4 billion
Write to Josée Rose at josee.rose@wsj.com
(END) Dow Jones Newswires
January 29, 2025 08:41 ET (13:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。